AU5886296A
(en)
|
1995-06-02 |
1996-12-18 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors
|
US5908858A
(en)
|
1996-04-05 |
1999-06-01 |
Sankyo Company, Limited |
1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
|
EP0892791B1
(en)
*
|
1996-04-12 |
2003-03-05 |
G.D. Searle & Co. |
N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS
|
US8022095B2
(en)
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
US6586458B1
(en)
|
1996-08-16 |
2003-07-01 |
Pozen Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
BR9807920A
(pt)
*
|
1997-04-03 |
2000-02-22 |
Searle & Co |
Processos para tratamento de uma demência em um sujeito e para prevenção de uma demência
|
US20040072889A1
(en)
*
|
1997-04-21 |
2004-04-15 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
|
RS49982B
(sr)
|
1997-09-17 |
2008-09-29 |
Euro-Celtique S.A., |
Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
|
US6887893B1
(en)
*
|
1997-12-24 |
2005-05-03 |
Sankyo Company, Limited |
Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
|
CA2322824A1
(en)
*
|
1998-03-13 |
1999-09-16 |
Merck & Co., Inc. |
Combination therapy and composition for acute coronary ischemic syndrome and related conditions
|
US6136804A
(en)
*
|
1998-03-13 |
2000-10-24 |
Merck & Co., Inc. |
Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
|
JP2002517423A
(ja)
|
1998-06-08 |
2002-06-18 |
アドバンスド メディスン インコーポレーテッド |
シクロオキシゲナーゼ−2の多結合インヒビター
|
AR024222A1
(es)
*
|
1998-10-16 |
2002-09-25 |
Palau Pharma Sa |
Imidazoles con actividad antiinflamatoria un procedimiento para su preparacion y composiciones farmaceuticas que lo contienen
|
AU759307B2
(en)
*
|
1998-11-02 |
2003-04-10 |
Merck Sharp & Dohme Corp. |
Method of treating migraines and pharmaceutical compositions
|
WO2000029022A1
(en)
*
|
1998-11-12 |
2000-05-25 |
Algos Pharmaceutical Corporation |
Cox-2 inhibitors in combination with centrally acting analgesics
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
US20040122011A1
(en)
*
|
1998-12-23 |
2004-06-24 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
|
US6649645B1
(en)
*
|
1998-12-23 |
2003-11-18 |
Pharmacia Corporation |
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
|
US20030119895A1
(en)
*
|
1998-12-23 |
2003-06-26 |
Pharmacia Corporation |
Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
|
WO2000048583A2
(en)
*
|
1999-02-19 |
2000-08-24 |
Pozen Inc. |
Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine
|
US20010024664A1
(en)
*
|
1999-03-19 |
2001-09-27 |
Obukowicz Mark G. |
Selective COX-2 inhibition from edible plant extracts
|
WO2001028548A1
(en)
*
|
1999-10-19 |
2001-04-26 |
Texas Heart Institute |
Treatment of heart disease with cox-2 inhibitors
|
BR0008060A
(pt)
*
|
1999-12-08 |
2002-02-05 |
Pharmacia Corp |
Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica
|
IL150353A0
(en)
*
|
1999-12-22 |
2002-12-01 |
Pharmacia Corp |
Dual-release compositions of a cyclooxygenase-2 inhibitor
|
BR0017037A
(pt)
|
1999-12-23 |
2003-06-10 |
Nitromed Inc |
Inibidores de ciclooxigenase-2 nitrosados e nitrosilados, composições e métodos de uso
|
CN1951899B
(zh)
|
2000-02-16 |
2012-02-01 |
布里格姆及妇女医院股份有限公司 |
阿司匹林触发的脂质介体
|
EP1259504A1
(en)
|
2000-03-03 |
2002-11-27 |
Pfizer Products Inc. |
Pyrazole ether derivatives as anti-inflammatory/analgesic agents
|
US20070072861A1
(en)
*
|
2000-03-27 |
2007-03-29 |
Barbara Roniker |
Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
|
EP1276736A2
(en)
*
|
2000-04-25 |
2003-01-22 |
Pharmacia Corporation |
Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
|
ES2166710B1
(es)
*
|
2000-04-25 |
2004-10-16 |
J. URIACH & CIA, S.A. |
Nuevos compuestos heterociclicos con actividad antiinflamatoria.
|
WO2002005848A2
(en)
*
|
2000-07-13 |
2002-01-24 |
Pharmacia Corporation |
Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
|
WO2002007721A2
(en)
|
2000-07-20 |
2002-01-31 |
Lauras As |
Use of cox-2 inhibitors for preventing immunodeficiency
|
US20030219461A1
(en)
*
|
2000-09-12 |
2003-11-27 |
Britten Nancy J. |
Parenteral combination therapy for infective conditions
|
EP1322311A1
(en)
*
|
2000-09-18 |
2003-07-02 |
Merck & Co., Inc. |
Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist
|
US20020173524A1
(en)
*
|
2000-10-11 |
2002-11-21 |
Tularik Inc. |
Modulation of CCR4 function
|
EP1363649A1
(en)
*
|
2000-12-15 |
2003-11-26 |
Pharmacia Corporation |
Selective cox-2 inhibition from non-edible plant extracts
|
US20020136784A1
(en)
*
|
2000-12-15 |
2002-09-26 |
Pharmacia Corporation |
Selective COX-2 inhibition from plant extracts
|
ATE338544T1
(de)
|
2000-12-21 |
2006-09-15 |
Nitromed Inc |
Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
US20030008870A1
(en)
*
|
2001-02-02 |
2003-01-09 |
Joel Krasnow |
Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dysmenorrhea
|
AU2002306868A1
(en)
*
|
2001-03-28 |
2002-10-15 |
Pharmacia Corporation |
Therapeutic combinations for cardiovascular and inflammatory indications
|
PE20021017A1
(es)
*
|
2001-04-03 |
2002-11-24 |
Pharmacia Corp |
Composicion parenteral reconstituible
|
ITMI20010733A1
(it)
|
2001-04-05 |
2002-10-05 |
Recordati Chem Pharm |
Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
|
US20030105144A1
(en)
|
2001-04-17 |
2003-06-05 |
Ping Gao |
Stabilized oral pharmaceutical composition
|
US6673818B2
(en)
*
|
2001-04-20 |
2004-01-06 |
Pharmacia Corporation |
Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
|
US7144903B2
(en)
*
|
2001-05-23 |
2006-12-05 |
Amgen Inc. |
CCR4 antagonists
|
US20030153801A1
(en)
*
|
2001-05-29 |
2003-08-14 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
|
US20030161867A1
(en)
*
|
2001-05-31 |
2003-08-28 |
Lu Guang Wei |
Skin-permeable selective cyclooxygenase-2 inhibitor composition
|
DE10129320A1
(de)
*
|
2001-06-19 |
2003-04-10 |
Norbert Mueller |
Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
|
US20060167074A1
(en)
*
|
2001-06-19 |
2006-07-27 |
Norbert Muller |
Methods and compositions for the treatment of psychiatric disorders
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
US20040067992A1
(en)
*
|
2001-08-10 |
2004-04-08 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
|
AU2002331050A1
(en)
*
|
2001-08-10 |
2003-02-24 |
Pharmacia Corporation |
Carbonic anhydrase inhibitors
|
US20050101563A1
(en)
*
|
2001-08-14 |
2005-05-12 |
Pharmacia Corporation |
Method and compositions for the treatment and prevention of pain and inflammation
|
US20030114416A1
(en)
*
|
2001-08-14 |
2003-06-19 |
Pharmacia Corporation |
Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
MXPA04002242A
(es)
*
|
2001-09-10 |
2005-03-07 |
Sugen Inc |
Derivados de 3-(4,5,6,7,-tetrahidroindol-2-ilmetiliden)-2-indolinona como inhibidores de cinasa.
|
US20030114483A1
(en)
*
|
2001-09-18 |
2003-06-19 |
Pharmacia Corporation |
Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
US6906196B2
(en)
*
|
2001-09-18 |
2005-06-14 |
Onconova Therapeutics, Inc. |
Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
|
AU2002330042A1
(en)
|
2001-09-18 |
2003-04-01 |
Onconova Therapeutics, Inc. |
Process for the preparation of 1,5-diarylpyrazoles
|
US20030236308A1
(en)
*
|
2001-09-18 |
2003-12-25 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
DE60220422T2
(de)
*
|
2001-09-19 |
2008-02-07 |
Pharmacia Corp. |
Substituierte pyrazol-verbindungen zur behandlung von entzündungen
|
MXPA04003072A
(es)
*
|
2001-10-02 |
2004-09-06 |
Pharmacia Corp |
Procedimiento para preparar compuestos de bencenosulfonilo.
|
AR037097A1
(es)
|
2001-10-05 |
2004-10-20 |
Novartis Ag |
Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
|
US6809204B2
(en)
*
|
2001-10-12 |
2004-10-26 |
Onconova Therapeutics, Inc. |
Processes for the preparation of substituted isoxazoles and 2-isoxazolines
|
US20030162824A1
(en)
*
|
2001-11-12 |
2003-08-28 |
Krul Elaine S. |
Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
|
WO2003041705A1
(en)
*
|
2001-11-13 |
2003-05-22 |
Pharmacia Corporation |
Oral dosage form of a sulfonamide prodrug such as parecoxib
|
DE60231439D1
(de)
|
2001-12-06 |
2009-04-16 |
Merck & Co Inc |
Mitotische kinesinhemmer
|
US20040126438A1
(en)
*
|
2001-12-13 |
2004-07-01 |
Obukowicz Mark G. |
Selective cox-2 inhibition from plant extracts
|
EP1463505A2
(en)
*
|
2001-12-13 |
2004-10-06 |
Abbott Laboratories |
3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
|
US20040062823A1
(en)
*
|
2001-12-13 |
2004-04-01 |
Obukowicz Mark G. |
Selective cox-2 inhibition from non-edible plant extracts
|
KR20040072720A
(ko)
*
|
2002-01-10 |
2004-08-18 |
파마시아 앤드 업존 캄파니 |
항바이러스제와 함께 사용되는 유두종 바이러스 감염의치료를 위한 cox-2 억제제의 용도
|
US20030220374A1
(en)
*
|
2002-01-14 |
2003-11-27 |
Pharmacia Corporation |
Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
|
US20030212138A1
(en)
*
|
2002-01-14 |
2003-11-13 |
Pharmacia Corporation |
Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
|
TW200403072A
(en)
*
|
2002-01-23 |
2004-03-01 |
Upjohn Co |
Combination therapy for the treatment of bacterial infections
|
WO2004026235A2
(en)
*
|
2002-09-20 |
2004-04-01 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical compositions with improved dissolution
|
US20100311701A1
(en)
*
|
2002-02-15 |
2010-12-09 |
Transform Pharmaceuticals, Inc |
Pharmaceutical Co-Crystal Compositions
|
US7927613B2
(en)
*
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
US7790905B2
(en)
*
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
EP1915992A1
(en)
|
2002-02-19 |
2008-04-30 |
Pharmacia Corporation |
Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
|
AU2003213719A1
(en)
|
2002-03-01 |
2003-09-16 |
Regents Of The University Of Michigan |
Multiple-component solid phases containing at least one active pharmaceutical ingredient
|
US20030232871A1
(en)
*
|
2002-03-15 |
2003-12-18 |
Sheikh Ahmad Y. |
Crystalline parecoxib sodium
|
US7902257B2
(en)
*
|
2002-04-01 |
2011-03-08 |
University Of Southern California |
Trihydroxy polyunsaturated eicosanoid
|
US8481772B2
(en)
|
2002-04-01 |
2013-07-09 |
University Of Southern California |
Trihydroxy polyunsaturated eicosanoid derivatives
|
BR0309014A
(pt)
|
2002-04-08 |
2005-01-11 |
Glaxo Group Ltd |
ácido(2-((2-alcóxi)-fenil)-ciclopent-1-enil)carbo e heterocìclico aromático e derivados
|
BR0309259A
(pt)
*
|
2002-04-18 |
2005-02-09 |
Pharmacia Corp |
Terapia combinada para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox 2)
|
JP2005532293A
(ja)
*
|
2002-04-18 |
2005-10-27 |
ファルマシア・コーポレーション |
シクロオキシゲナーゼ−2(cox2)阻害剤を用いたパーキンソン病の治療のための単剤療法
|
AU2003229016A1
(en)
*
|
2002-05-10 |
2003-11-11 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagatingvaricella zoster virus and methods of use thereof
|
CA2489984A1
(en)
*
|
2002-06-21 |
2003-12-31 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical compositions with improved dissolution
|
MXPA05000011A
(es)
*
|
2002-06-26 |
2005-04-08 |
Pharmacia Corp |
Formulacion parenteral liquida estable de parecoxib.
|
US7087630B2
(en)
|
2002-06-27 |
2006-08-08 |
Nitromed, Inc. |
Cyclooxygenase 2 selective inhibitors, compositions and methods of use
|
WO2004002420A2
(en)
|
2002-06-28 |
2004-01-08 |
Nitromed, Inc. |
Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
|
US20040063697A1
(en)
*
|
2002-07-02 |
2004-04-01 |
Isakson Peter C. |
Compositions of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event
|
US7759395B2
(en)
|
2002-08-12 |
2010-07-20 |
The Brigham And Women's Hospital, Inc. |
Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
|
EP1537067B1
(en)
*
|
2002-08-12 |
2009-11-18 |
Brigham And Women's Hospital |
Resolvins: biotemplates for therapeutic interventions
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
KR100484525B1
(ko)
*
|
2002-10-15 |
2005-04-20 |
씨제이 주식회사 |
이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
|
US20040082543A1
(en)
*
|
2002-10-29 |
2004-04-29 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
|
GB0225548D0
(en)
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Compounds
|
US20040092566A1
(en)
*
|
2002-11-12 |
2004-05-13 |
Graneto Matthew J. |
Celecoxib prodrug
|
US20040147581A1
(en)
*
|
2002-11-18 |
2004-07-29 |
Pharmacia Corporation |
Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
|
US20040127531A1
(en)
*
|
2002-11-21 |
2004-07-01 |
Lu Guang Wei |
Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor
|
US20050020658A1
(en)
*
|
2002-11-21 |
2005-01-27 |
Katsuyuki Inoo |
Selective cyclooxygenase-2 inhibitor patch
|
US20040126415A1
(en)
*
|
2002-11-21 |
2004-07-01 |
Lu Guang Wei |
Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor
|
ES2341240T3
(es)
|
2002-12-13 |
2010-06-17 |
Warner-Lambert Company Llc |
Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
|
US20040204411A1
(en)
*
|
2002-12-17 |
2004-10-14 |
Pharmacia Corporation |
Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
|
US20040235925A1
(en)
*
|
2002-12-17 |
2004-11-25 |
Pharmacia Corporation |
Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
|
EP1572186A2
(en)
*
|
2002-12-19 |
2005-09-14 |
Pharmacia Corporation |
Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
|
US20080153894A1
(en)
*
|
2002-12-19 |
2008-06-26 |
Pharmacia Corporation |
Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
|
WO2004058354A1
(en)
*
|
2002-12-20 |
2004-07-15 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
|
ES2215474B1
(es)
|
2002-12-24 |
2005-12-16 |
J. URIACH & CIA S.A. |
Nuevos derivados de fosforamida.
|
JP4616009B2
(ja)
|
2002-12-26 |
2011-01-19 |
ポーゼン インコーポレイテッド |
NSAIDsおよびトリプタンを含有する多層剤型
|
US8183290B2
(en)
*
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
WO2004060367A1
(en)
*
|
2002-12-30 |
2004-07-22 |
Fujisawa Pharmaceutical Co., Ltd. |
Imidazole and triazole derivatives useful as selective cox-1 inhibitors
|
US20050026902A1
(en)
*
|
2003-01-31 |
2005-02-03 |
Timothy Maziasz |
Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
|
US20040176378A1
(en)
*
|
2003-02-12 |
2004-09-09 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system
|
WO2004078143A2
(en)
*
|
2003-03-05 |
2004-09-16 |
The Brigham And Women's Hospital Inc. |
Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
|
DK1608407T3
(da)
*
|
2003-03-20 |
2006-12-04 |
Pharmacia Corp |
Dispergébar formulering af et antiinflammatorisk middel
|
US20050004098A1
(en)
*
|
2003-03-20 |
2005-01-06 |
Britten Nancy Jean |
Dispersible formulation of an anti-inflammatory agent
|
US20040214753A1
(en)
*
|
2003-03-20 |
2004-10-28 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
US20050009931A1
(en)
*
|
2003-03-20 |
2005-01-13 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
US20040220155A1
(en)
*
|
2003-03-28 |
2004-11-04 |
Pharmacia Corporation |
Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
|
US20040214861A1
(en)
*
|
2003-03-28 |
2004-10-28 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
|
AU2003238669A1
(en)
*
|
2003-04-04 |
2004-10-25 |
Hetero Drugs Limited |
Novel crystalline forms of parecoxib sodium
|
WO2004092146A2
(en)
*
|
2003-04-14 |
2004-10-28 |
The Institutes For Pharmaceutical Discovery, Llc |
N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
|
WO2004093895A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
|
US20040224940A1
(en)
*
|
2003-04-22 |
2004-11-11 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage
|
US20050159403A1
(en)
*
|
2003-04-22 |
2005-07-21 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
|
WO2004093814A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker
|
WO2004093813A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
|
WO2004093896A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
|
EP1620420A2
(en)
|
2003-04-30 |
2006-02-01 |
The Institutes for Pharmaceutical Discovery, LLC |
Substituted carboxylic acids
|
US20040220167A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Nasrollah Samiy |
Methods of treating neuralgic pain
|
DE602004002832T2
(de)
|
2003-05-07 |
2007-06-06 |
Osteologix A/S |
Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
|
US20050107387A1
(en)
*
|
2003-05-13 |
2005-05-19 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
|
US20050159471A1
(en)
*
|
2003-05-14 |
2005-07-21 |
Pharmacia Corporation |
Compositions of a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
|
WO2004103286A2
(en)
*
|
2003-05-14 |
2004-12-02 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cholimergic agent
|
WO2004103283A2
(en)
*
|
2003-05-14 |
2004-12-02 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
|
EP1628650A1
(en)
*
|
2003-05-14 |
2006-03-01 |
Pharmacia Corporation |
Compositions for the treatment of reduced blood flow
|
US20050113376A1
(en)
*
|
2003-05-27 |
2005-05-26 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury
|
US20060160776A1
(en)
*
|
2003-05-28 |
2006-07-20 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
|
JP4901474B2
(ja)
|
2003-05-30 |
2012-03-21 |
ランバクシー ラボラトリーズ リミテッド |
置換ピロール誘導体
|
US20050054646A1
(en)
*
|
2003-06-09 |
2005-03-10 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
|
BRPI0411731A
(pt)
*
|
2003-06-24 |
2006-08-08 |
Pharmacia Corp |
tratamento de enxaqueca acompanhada por náusea
|
WO2005007106A2
(en)
*
|
2003-07-10 |
2005-01-27 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a non-nmda glutamate modulator for the treatment of central nervous system damage
|
WO2005007156A1
(en)
*
|
2003-07-10 |
2005-01-27 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin ii receptor antagonist for the treatment of central nervous system damage
|
WO2005018541A2
(en)
*
|
2003-07-11 |
2005-03-03 |
Pharmacia Corporation |
Cox-2 inhibitor and serotonin modulator for treating cns damage
|
WO2005016249A2
(en)
*
|
2003-07-11 |
2005-02-24 |
Pharmacia Corporation |
Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ace inhibitor for the treatment of central nervous system damage
|
WO2005009342A2
(en)
*
|
2003-07-16 |
2005-02-03 |
Pharmacia Corporation |
Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
|
US20050075341A1
(en)
*
|
2003-07-17 |
2005-04-07 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
|
JPWO2005012268A1
(ja)
*
|
2003-07-30 |
2006-09-14 |
塩野義製薬株式会社 |
イソオキサゾール環を有するスルホンアミド誘導体
|
AU2004266705A1
(en)
*
|
2003-08-20 |
2005-03-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
|
US20050119262A1
(en)
*
|
2003-08-21 |
2005-06-02 |
Pharmacia Corporation |
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
|
WO2005018563A2
(en)
*
|
2003-08-22 |
2005-03-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
|
US20050107350A1
(en)
*
|
2003-08-22 |
2005-05-19 |
Pharmacia Corporation |
Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
|
WO2005018564A2
(en)
*
|
2003-08-22 |
2005-03-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
|
BRPI0413679A
(pt)
*
|
2003-08-22 |
2006-10-24 |
Pharmacia Corp |
formulações de um inibidor seletivo da ciclooxigenase-2 e de um agente de modulação da serotonina para o tratamento da neoplasia
|
WO2005020910A2
(en)
*
|
2003-08-27 |
2005-03-10 |
Pharmacia Corporation |
Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
|
US7282519B2
(en)
*
|
2003-08-28 |
2007-10-16 |
Nitromed, Inc. |
Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
WO2005023189A2
(en)
*
|
2003-09-03 |
2005-03-17 |
Pharmacia Corporation |
Method of cox-2 selective inhibitor and nitric oxide-donating agent
|
WO2005037193A2
(en)
*
|
2003-10-03 |
2005-04-28 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury
|
BRPI0415939A
(pt)
*
|
2003-11-12 |
2007-01-02 |
Pharmacia & Upjohn Co Llc |
composições de um inibidor seletivo da ciclooxigenase-2 e um agente de modulação do fator neurotrófico para o tratamento de distúrbios mediados pelo sistema nervoso central
|
BRPI0417197A
(pt)
*
|
2003-12-24 |
2007-03-06 |
Pharmacia Corp |
sais de metais de parecoxib como pró-drogas do inibidor de cox-2 valdecoxib para tratamento de inflamação, dor e/ou febre
|
BRPI0506994A
(pt)
|
2004-01-22 |
2007-07-03 |
Pfizer |
derivados de triazol que inibem a atividade antagonista da vasopressina
|
WO2005105025A1
(en)
*
|
2004-04-14 |
2005-11-10 |
Boston University |
Methods and compositions for preventing or treating periodontal diseases
|
WO2005105779A1
(en)
*
|
2004-04-28 |
2005-11-10 |
Pfizer Limited |
3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
|
BRPI0512832A
(pt)
|
2004-07-01 |
2008-04-08 |
Merck & Co Inc |
composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para usar um composto
|
ES2257929B1
(es)
|
2004-07-16 |
2007-05-01 |
Laboratorios Del Dr. Esteve, S.A. |
Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
|
RU2007101510A
(ru)
*
|
2004-07-22 |
2008-08-27 |
Фармаци Корпорейшн (US) |
Композиции для лечения воспаления и боли с использованием комбинации селективного ингибитора сох-2 и антагониста рецептора ltb4
|
WO2006041855A2
(en)
|
2004-10-04 |
2006-04-20 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
WO2006052899A2
(en)
*
|
2004-11-08 |
2006-05-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
|
MX2007007830A
(es)
|
2004-12-23 |
2007-07-25 |
Glaxo Group Ltd |
Compuestos de piridina para el tratamiento de enfermedades mediadas por prostaglandina.
|
US20080306041A1
(en)
*
|
2005-01-21 |
2008-12-11 |
Garvey David S |
Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
|
CA2597422A1
(en)
*
|
2005-02-16 |
2007-08-02 |
Nitromed, Inc. |
Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
|
US7521435B2
(en)
*
|
2005-02-18 |
2009-04-21 |
Pharma Diagnostics, N.V. |
Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
|
EP1858863A1
(en)
*
|
2005-02-28 |
2007-11-28 |
Nitromed, Inc. |
Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
|
KR100990027B1
(ko)
|
2005-04-26 |
2010-10-26 |
화이자 인코포레이티드 |
P-카드헤린 항체
|
WO2006121887A2
(en)
*
|
2005-05-05 |
2006-11-16 |
Cook Biotech Incorporated |
Implantable materials and methods for inhibiting tissue adhesion formation
|
ES2382814T3
(es)
|
2005-05-17 |
2012-06-13 |
Merck Sharp & Dohme Ltd. |
Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
|
CA2608718A1
(en)
*
|
2005-05-18 |
2006-11-23 |
Pfizer Limited |
1, 2, 4-triazole derivatives as vasopressin antagonists
|
EP1883614A4
(en)
*
|
2005-05-23 |
2010-04-14 |
Nicox Sa |
ORGANIC NITRIC OXIDES IMPROVING SALTS FROM NON-SUBSTITUTE INFLAMMATORY COMPOUNDS AND COMPOSITIONS AND USES THEREOF
|
HUP0500730A2
(en)
*
|
2005-07-29 |
2007-02-28 |
Richter Gedeon Vegyuszeti Gyar |
1,2-diaryl-heterocyclic compounds, their preparation, pharmaceutical compositions comprising thereof and their use
|
US20090018091A1
(en)
*
|
2005-08-02 |
2009-01-15 |
Nitromed, Inc. |
Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
|
TWI387592B
(zh)
|
2005-08-30 |
2013-03-01 |
Novartis Ag |
經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
|
US7537762B2
(en)
|
2005-09-07 |
2009-05-26 |
Amgen Fremont, Inc. |
Human monoclonal antibodies to activin receptor-like kinase-1
|
US8273792B2
(en)
*
|
2005-10-03 |
2012-09-25 |
The Brigham And Women's Hospital, Inc. |
Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
|
CA2624933A1
(en)
*
|
2005-10-04 |
2007-04-12 |
Nitromed, Inc. |
Methods for treating respiratory disorders
|
SG166829A1
(en)
|
2005-11-08 |
2010-12-29 |
Ranbaxy Lab Ltd |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
EP1954685A4
(en)
*
|
2005-11-16 |
2009-11-11 |
Nitromed Inc |
FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
|
EP1954291A1
(en)
*
|
2005-11-18 |
2008-08-13 |
Trustees Of Boston University |
Treatment and prevention of bone loss using resolvins
|
EP1968584A2
(en)
*
|
2005-12-20 |
2008-09-17 |
Nitromed, Inc. |
Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
|
NL2000351C2
(nl)
|
2005-12-22 |
2007-09-11 |
Pfizer Prod Inc |
Estrogeen-modulatoren.
|
US20080293702A1
(en)
*
|
2005-12-22 |
2008-11-27 |
Nitromed, Inc. |
Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use
|
WO2007087246A2
(en)
|
2006-01-24 |
2007-08-02 |
Merck & Co., Inc. |
Jak2 tyrosine kinase inhibition
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
AU2007243765A1
(en)
|
2006-03-29 |
2007-11-08 |
Nicox S.A. |
Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
|
US7553854B2
(en)
|
2006-04-19 |
2009-06-30 |
Novartis Vaccines And Diagnostics, Inc. |
6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
|
AU2007254179B2
(en)
|
2006-05-18 |
2013-03-21 |
Pharmacyclics Llc |
Intracellular kinase inhibitors
|
WO2008033931A1
(en)
*
|
2006-09-13 |
2008-03-20 |
The Institutes For Pharmaceutical Discovery, Llc |
Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib
|
EP2946778A1
(en)
|
2006-09-22 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
DK2125021T3
(da)
|
2006-12-22 |
2011-09-19 |
Recordati Ireland Ltd |
Kombinationsterapi af sygdomme i de nedre urinveje med alfa2delta-ligander og NSAID'er
|
KR101591656B1
(ko)
|
2007-01-10 |
2016-02-19 |
엠에스디 이탈리아 에스.알.엘. |
폴리(adp-리보오스) 폴리머라아제(parp) 억제제로서의 아미드 치환된 인다졸
|
KR100843351B1
(ko)
*
|
2007-01-30 |
2008-07-03 |
한국과학기술연구원 |
중추신경계 질환 치료제로 유효한n-벤질-n-(2-디메틸아미노-에틸)-벤젠술폰아미드 화합물
|
AU2008221263B2
(en)
|
2007-03-01 |
2012-02-23 |
Novartis Ag |
Pim kinase inhibitors and methods of their use
|
GB0704407D0
(en)
|
2007-03-07 |
2007-04-18 |
Glaxo Group Ltd |
Compounds
|
EP2152700B1
(en)
|
2007-05-21 |
2013-12-11 |
Novartis AG |
Csf-1r inhibitors, compositions, and methods of use
|
WO2009002495A1
(en)
|
2007-06-27 |
2008-12-31 |
Merck & Co., Inc. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
AU2008274941A1
(en)
|
2007-07-12 |
2009-01-15 |
Tragara Pharmaceuticals, Inc. |
Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
|
US7943658B2
(en)
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
KR101257550B1
(ko)
|
2007-09-10 |
2013-04-24 |
칼시메디카, 인크 |
세포내 칼슘을 조절하는 화합물
|
AU2009222122A1
(en)
|
2008-03-03 |
2009-09-11 |
Tiger Pharmatech |
Tyrosine kinase inhibitors
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
CA2734500A1
(en)
|
2008-08-27 |
2010-03-11 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
EP2177215A1
(en)
|
2008-10-17 |
2010-04-21 |
Laboratorios Del. Dr. Esteve, S.A. |
Co-crystals of tramadol and NSAIDs
|
JP5212177B2
(ja)
*
|
2009-02-27 |
2013-06-19 |
東レ株式会社 |
γ−ケトアセタール化合物及びピロール誘導体の製造方法
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
KR101069175B1
(ko)
|
2009-04-19 |
2011-09-30 |
중앙대학교 산학협력단 |
신규 아미노설포닐아릴이소옥사졸계 화합물 및 이를 포함하는 다약제내성 억제용 약제학적 조성물
|
WO2011012622A1
(en)
|
2009-07-30 |
2011-02-03 |
Glaxo Group Limited |
Benzoxazinone derivatives for the treatment of glytl mediated disorders
|
WO2011023753A1
(en)
|
2009-08-27 |
2011-03-03 |
Glaxo Group Limited |
Benzoxazine derivatives as glycine transport inhibitors
|
EP2488028B1
(en)
|
2009-10-14 |
2020-08-19 |
Merck Sharp & Dohme Corp. |
Substituted piperidines that increase p53 activity and the uses thereof
|
GB201000685D0
(en)
|
2010-01-15 |
2010-03-03 |
Glaxo Group Ltd |
Novel compounds
|
CN101805290A
(zh)
*
|
2010-04-01 |
2010-08-18 |
中国人民解放军第四军医大学 |
氨基磺酰吡唑类化合物及其用途
|
DK2563776T3
(en)
|
2010-04-27 |
2016-09-19 |
Calcimedica Inc |
Relations that modulate intracellular calcium
|
CA2797533A1
(en)
|
2010-04-27 |
2011-11-10 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
GB201007791D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel compounds
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
EP2571860A1
(en)
|
2010-05-21 |
2013-03-27 |
Pfizer Inc |
2-phenyl benzoylamides
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
WO2012004604A1
(en)
|
2010-07-09 |
2012-01-12 |
Convergence Pharmaceuticals Limited |
Tetrazole compounds as calcium channel blockers
|
WO2012018754A2
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
AU2011292261B2
(en)
|
2010-08-17 |
2015-05-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
RU2013111971A
(ru)
*
|
2010-08-20 |
2014-09-27 |
Аллерган, Инк. |
Соединения, действующие на множественные рецепторы простагландина, дающие общую противовоспалительную реакцию
|
WO2012027236A1
(en)
|
2010-08-23 |
2012-03-01 |
Schering Corporation |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
AU2011293201B2
(en)
|
2010-08-27 |
2015-11-05 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
ES2663009T3
(es)
|
2010-10-29 |
2018-04-10 |
Sirna Therapeutics, Inc. |
Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
EP2665729B1
(en)
|
2011-01-19 |
2015-04-01 |
Convergence Pharmaceuticals Limited |
Piperazine derivatives as cav2.2 calcium channel blockers
|
EP2680874A2
(en)
|
2011-03-04 |
2014-01-08 |
Pfizer Inc |
Edn3-like peptides and uses thereof
|
EP2699568A1
(en)
|
2011-04-21 |
2014-02-26 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
WO2013066729A1
(en)
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
|
JP2015501802A
(ja)
*
|
2011-11-17 |
2015-01-19 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate |
眼への薬物送達を向上させるための方法および組成物、ならびに徐放性送達製剤
|
GB201122113D0
(en)
|
2011-12-22 |
2012-02-01 |
Convergence Pharmaceuticals |
Novel compounds
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
WO2014052563A2
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
CA2892361A1
(en)
|
2012-11-28 |
2014-06-05 |
Merck Sharp & Dohme Corp. |
Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
|
AU2013361694B2
(en)
|
2012-12-20 |
2017-10-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as HDM2 inhibitors
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
CA2911376C
(en)
*
|
2013-03-15 |
2021-03-30 |
University Of Southern California |
Phenyl(sulfonylcarbamate) derivatives and pharmaceutical compositions thereof for the treatment of angiotensin-related diseases
|
US20160166576A1
(en)
|
2013-07-11 |
2016-06-16 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
CN104418818B
(zh)
*
|
2013-09-04 |
2017-01-11 |
天津汉瑞药业有限公司 |
帕瑞昔布钠无水化合物
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
CN105085425B
(zh)
*
|
2014-05-23 |
2018-01-30 |
昆药集团股份有限公司 |
一种制备帕瑞昔布的方法
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
GB201417500D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417497D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417499D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
CN104557754A
(zh)
*
|
2015-01-04 |
2015-04-29 |
成都克莱蒙医药科技有限公司 |
一种帕瑞昔布钠杂质的合成方法
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
EP3267996B1
(en)
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of irak4 activity
|
WO2016144849A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of irak4 activity
|
SI3328827T1
(sl)
*
|
2015-07-31 |
2023-11-30 |
The Johns Hopkins University |
Predzdravila glutamin analogov
|
US9598361B1
(en)
*
|
2016-04-12 |
2017-03-21 |
King Saud University |
Amino substituted acetamide derivative
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
CN108299331A
(zh)
*
|
2018-03-02 |
2018-07-20 |
成都新恒创药业有限公司 |
一种帕瑞昔布钠光降解杂质及其制备、检测方法和应用
|
CN108164521B
(zh)
*
|
2018-03-02 |
2020-11-13 |
成都新恒创药业有限公司 |
一种帕瑞昔布钠降解杂质及其制备、检测方法和应用
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
CN110305071A
(zh)
*
|
2019-07-23 |
2019-10-08 |
成都通德药业有限公司 |
一种帕瑞昔布钠中间体帕瑞昔布的合成方法
|
CA3160153A1
(en)
|
2019-12-17 |
2021-06-24 |
Michelle Machacek |
Prmt5 inhibitors
|
CA3209491A1
(en)
|
2021-03-15 |
2022-09-22 |
Saul Yedgar |
Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease
|
CN115784991A
(zh)
*
|
2022-11-22 |
2023-03-14 |
合肥医工医药股份有限公司 |
N-(苯磺酰基)酰胺衍生物及其制备方法和用途
|